# Hematopoietic Biorepository and Cellular Therapy Shared Resource

> **NIH NIH P30** · CASE WESTERN RESERVE UNIVERSITY · 2021 · $127,044

## Abstract

HEMATOPOIETIC BIOREPOSITORY AND CELLULAR THERAPY SHARED RESOURCE 
PROJECT SUMMARY/ABSTRACT 
The Hematopoietic Biorepository and Cellular Therapy Shared Resource (Hematopoietic SR) is an essential 
asset to Case Comprehensive Cancer Center (Case CCC) members' research, illustrated by the breadth of 
scientific program involvement and reflected in the large number of investigators who use this SR. Last year 
alone, over 50 investigators, 51% of whom were Case CCC members, accounting for 68% of total usage, from 
all 7 of the Center’s Programs used the SR. The mission of the Hematopoietic SR is to provide resources and 
services related to the procurement, processing, production, storage, banking, analysis and distribution of cells 
derived from human blood, bone marrow, and umbilical cords. The SR also operates a Clinical Cellular 
Therapy facility that supports clinical-grade cell manufacturing for investigational and standard of care therapy. 
The Specific Aims of the Hematopoietic SR are to: 
 1. Enable access to annotated clinical blood and bone marrow samples to support basic and translational 
 research. An active IRB is maintained to consent and procure blood and bone marrow samples and 
 related case and tissue data from cancer patients and healthy donors for distribution to Case CCC 
investigators. 
 2. Assist users with specialized hematopoietic cell assays. Guidance and services are provided to enable 
 investigators to perform specialized hematopoietic cell assays such as colony assays. 
 3. Support the development and implementation of cellular therapy clinical trials. Support is provided in all 
 aspects of clinical cell therapy, from assisting with regulatory approval to oversight and manufacture of 
 clinical grade cells. 
At last review, the Hematopoietic SR was rated Excellent merit. Throughout the current funding cycle (2012- 
2016), the Hematopoietic SR provided services to 106 registered users, 44 (42%) of whom are Case CCC 
members, representing all 7 of the Case CCC programs. 
The Hematopoietic SR maintains a biorepository of annotated collected samples for use in research and 
assists investigators with specialized hematopoietic assays such as CFU assays and bone marrow-derived 
mesenchymal stem cell isolation. The cellular therapy component of the SR, designated as the Cellular 
Therapy Service, supports clinical cellular therapy activities from the preclinical phase through clinical trial 
implementation. Support capabilities include assistance in the design and preparation of cells for Good 
Laboratory Practices (GLP) safety studies, navigation of the regulatory pathway, clinical protocol development, 
Investigational New Drug Application (IND) preparation, sourcing of clinical grade supplies and reagents, and 
scale up from research to clinical operations, including preparation of investigational clinical therapy grade 
cellular products.

## Key facts

- **NIH application ID:** 10135929
- **Project number:** 5P30CA043703-31
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** Lan Zhou
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $127,044
- **Award type:** 5
- **Project period:** 1997-08-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10135929

## Citation

> US National Institutes of Health, RePORTER application 10135929, Hematopoietic Biorepository and Cellular Therapy Shared Resource (5P30CA043703-31). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10135929. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*